Showing results (41-50 of 154) with videos related to
Sort By:
Pageof 16
Blood Advances|September 23, 2021
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapyHussein A Abbas, Zoe Alaniz, Sean Mackay, et al.Medrxiv : the Preprint Server for Health Sciences|April 29, 2025
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53Li Li, Muharrem Muftuoglu, Edward Ayoub, et al.British Journal of Haematology|April 11, 2024
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expressionWei-Ying Jen, Koji Sasaki, Sanam Loghavi, et al.Frontiers in Oncology|November 16, 2020
Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.Genes|August 26, 2022
PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid LeukemiaLulu Wang, Wei Wang, Hannah C Beird, et al.Blood Cancer Journal|November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guideWei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.American Journal of Hematology|July 24, 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib eraFadi G Haddad, Koji Sasaki, Aram Bidikian, et al.Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.Journal of Hematology & Oncology|January 5, 2019
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceKamal Chamoun, Hagop Kantarjian, Rami Atallah, et al.American Journal of Hematology|September 2, 2022
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysisElias Jabbour, Koji Sasaki, Fadi G Haddad, et al.Pageof 16